Clinical trial
A Safety and Feasibility Study to Evaluate Blood-Brain Barrier Disruption Using Exablate MR-Guided Low Intensity Focused Ultrasound With Microbubbles in Combination With Preferentially Expressed Antigen of Melanoma (PRAME), Survivin, and Wilms Tumor 1 (WT1)-Targeting Tumor Associated Antigen-specific T-Cell Infusion in Patients With Newly Diagnosed Diffuse Midline Glioma (LIFT)
NCT07796061 is registered in ClinicalTrials.gov with Children's National Research Institute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Safety and Feasibility Study to Evaluate Blood-Brain Barrier Disruption Using Exablate MR-Guided Low Intensity Focused Ultrasound With Microbubbles in Combination With Preferentially Expressed Antigen of Melanoma (PRAME), Survivin, and Wilms Tumor 1 (WT1)-Targeting Tumor Associated Antigen-specific T-Cell Infusion in Patients With Newly Diagnosed Diffuse Midline Glioma (LIFT)
- Lead sponsor
- Children's National Research Institute
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- October 31, 2026
- Completion date
- December 31, 2032
- Enrollment
- 45 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
diffuse intrinsic pontine glioma, pontine diffuse midline glioma, thalamic diffuse midline glioma